Pharmaceuticals News and Research

RSS
Stevens Institute of Technology to host conference on bacteria-material interactions

Stevens Institute of Technology to host conference on bacteria-material interactions

3 Jun 2011
Teva completes patient enrollment in COPAXONE Phase III trial for treatment of multiple sclerosis

Teva completes patient enrollment in COPAXONE Phase III trial for treatment of multiple sclerosis

3 Jun 2011
Syndax receives U.S. patent for entinostat to treat metastatic cancers

Syndax receives U.S. patent for entinostat to treat metastatic cancers

3 Jun 2011
Green tea consumption increases number of 'regulatory T cells', prevents autoimmune disease

Green tea consumption increases number of 'regulatory T cells', prevents autoimmune disease

3 Jun 2011
FDA approves Mylan's ANDA for Venlafaxine HCl ER Capsules to treat depressive, anxiety disorder

FDA approves Mylan's ANDA for Venlafaxine HCl ER Capsules to treat depressive, anxiety disorder

3 Jun 2011
Protox reports net and comprehensive loss of $2.2 million for first quarter 2011

Protox reports net and comprehensive loss of $2.2 million for first quarter 2011

2 Jun 2011
Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

2 Jun 2011
AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

2 Jun 2011
Teva receives FDA approval to market Eisai's Alzheimer's treatment Aricept Tablets in the U.S.

Teva receives FDA approval to market Eisai's Alzheimer's treatment Aricept Tablets in the U.S.

2 Jun 2011
Sanofi, DNDi announce three-year research collaboration for neglected tropical diseases

Sanofi, DNDi announce three-year research collaboration for neglected tropical diseases

2 Jun 2011
PCF funds 14 new Creativity Awards for advanced prostate cancer research

PCF funds 14 new Creativity Awards for advanced prostate cancer research

2 Jun 2011
Anadys receives U.S. patent for setrobuvir to treat chronic hepatitis C

Anadys receives U.S. patent for setrobuvir to treat chronic hepatitis C

2 Jun 2011
Somnus Therapeutics completes SKP-1041 Phase 2 trial against sleep maintenance insomnia

Somnus Therapeutics completes SKP-1041 Phase 2 trial against sleep maintenance insomnia

2 Jun 2011
Fero Industries completes Sucanon human clinical trials on Type-2 diabetes

Fero Industries completes Sucanon human clinical trials on Type-2 diabetes

2 Jun 2011
Viewpoints: More on Medicare's 'hard choices'; elderly and anti-psychotics; Calif. insurance rate hikes

Viewpoints: More on Medicare's 'hard choices'; elderly and anti-psychotics; Calif. insurance rate hikes

2 Jun 2011
China's SFDA grants production license to TPI anti-diabetic drug Gliclazide

China's SFDA grants production license to TPI anti-diabetic drug Gliclazide

1 Jun 2011
Alexion's sBLA for Soliris receives FDA Priority Review designation to treat aHUS

Alexion's sBLA for Soliris receives FDA Priority Review designation to treat aHUS

1 Jun 2011
Non-invasive trigeminal nerve stimulation shows promise for drug-resistant epilepsy

Non-invasive trigeminal nerve stimulation shows promise for drug-resistant epilepsy

1 Jun 2011
Shield raises EUR8.2M through Series A financing

Shield raises EUR8.2M through Series A financing

1 Jun 2011
UNICEF publishes vaccine costs in an effort to promote price competition

UNICEF publishes vaccine costs in an effort to promote price competition

1 Jun 2011

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback